CAM
MRTX

Cormorant Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Cormorant Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-400,000
Closed -$18.1M – 84
2022
Q4 		$18.1M Sell
400,000
-175,000
-30% -$11.3M 1.21% 29
2022
Q3 		$40.2M Buy
575,000
+275,000
+92% +$20.3M 2.81% 8
2022
Q2 		$20.1M Buy
300,000
+250,000
+500% +$15.9M 1.52% 24
2022
Q1 		$4.11M Sell
50,000
-25,000
-33% -$2.56M 0.32% 54
2021
Q4 		$11M Sell
75,000
-45,000
-38% -$6.99M 0.65% 41
2021
Q3 		$21.2M Sell
120,000
-55,000
-31% -$8.85M 0.86% 33
2021
Q2 		$28.3M Sell
175,000
-100,000
-36% -$16.1M 0.96% 29
2021
Q1 		$47.1M Sell
275,000
-50,000
-15% -$9.9M 1.05% 23
2020
Q4 		$71.4M Buy
325,000
+50,000
+18% +$10.8M 1.7% 21
2020
Q3 		$45.7M Sell
275,000
-225,000
-45% -$30.8M 1.76% 20
2020
Q2 		$57.1M Sell
500,000
-350,000
-41% -$33.9M 2.18% 17
2020
Q1 		$65.3M Sell
850,000
-432,392
-34% -$38.8M 3.04% 9
2019
Q4 		$165M Sell
1,282,392
-317,608
-20% -$30.6M 6.59% 3
2019
Q3 		$125M Buy
1,600,000
+500,000
+45% +$46.9M 7.59% 2
2019
Q2 		$113M Buy
1,100,000
+25,000
+2% +$1.95M 6.51% 2
2019
Q1 		$78.8M Sell
1,075,000
-676,699
-39% -$46M 5.33% 3
2018
Q4 		$74.3M Sell
1,751,699
-58,301
-3% -$2.32M 6.03% 2
2018
Q3 		$85.3M Sell
1,810,000
-108,350
-6% -$6.03M 5.54% 2
2018
Q2 		$94.6M Hold
1,918,350
– – 7% 2
2018
Q1 		$58.9M Buy
1,918,350
+686,828
+56% +$19.1M 4.39% 5
2017
Q4 		$22.5M Buy
1,231,522
+231,522
+23% +$3.59M 2.35% 12
2017
Q3 		$11.7M Buy
+1,000,000
New +$5.79M 2.07% 17
2016
Q2 		– Sell
-495,356
Closed -$10.6M – 91
2016
Q1 		$10.6M Hold
495,356
– – 1.6% 25
2015
Q4 		$15.7M Buy
495,356
+240,356
+94% +$8.49M 1.87% 17
2015
Q3 		$8.78M Buy
+255,000
New +$7.71M 1.4% 26

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Cormorant Asset Management's MRTX Position: Q1 2023 in Review

Cormorant Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 400,000 shares — an estimated $18.1M sold.

Cormorant Asset Management first reported a position in MRTX in Q3 2015 and held it in 25 quarters. The position peaked at $165M in Q4 2019. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

  • Cormorant Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 400,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $18.1M.
  • Cormorant Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 25 quarters.
  • Cormorant Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $165M in Q4 2019.
  • 221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Cormorant Asset Management's 13F filing for Q1 2023, filed 15 May 2023.